ALT › analyze
ALT · Analyze smallcap
Archetype: HYBRID — Turnaround shell, Startup mechanics. ALT traded far higher before its February 2025 MASH disappointment and sits at $2.94 against a $6.44 52-week high. That is the Turnaround profile. But it is a pre-revenue clinical-stage biotech with no product and no commercial operation, which is Startup mechanics. Both lenses applied. Base rate ~10% either way.
Risk rating: ASYMMETRIC-BET · Conviction 6.0 · 14 red flags / 9 golden flags
1. The number that frames everything
| Market capitalisation (at $2.94) | $571.7M |
| Cash, equivalents and restricted | $63.05M |
| Short-term investments | $263.27M |
| Long-term investments | $192.25M |
| Total liquidity (company-confirmed: "$519 million") | $518.57M |
| Less: term loan | ($34.74M) |
| Net liquidity | ~$483.9M |
| Implied enterprise value | ~$88M |
The market is valuing the entire pemvidutide franchise at roughly $88M — a Phase 3-stage asset with Breakthrough Therapy Designation in MASH, Fast Track in AUD, and a positive Phase 2 readout three weeks ago. Net liquidity is $2.49 per share against a $2.94 price. You pay about 45 cents a share for the pipeline.
Caveat that must travel with that number. Cash per share is a floor only for a company that is liquidating. ALT is doing the opposite — it started a global Phase 3 in August. That $2.49 is committed to being spent, not returned. The low EV is a statement about time and dilution risk, not a free lunch. It is still the most striking valuation anomaly across the seven names screened.
Correction to the widely circulated figure: commentary citing "$332M in liquidity" is counting only cash plus short-term investments and missing the $192.3M of long-term investments added in Q2. The company's own Q2 release headlines $519M.
2. RED FLAGS — front and center
| # | Flag | Detail |
|---|---|---|
| 1 | Share count +75.4% in six months | 110,882,735 (2025-12-31) → 130,221,154 (2026-03-31) → 194,474,154 (2026-06-30). The runway was bought with ownership. |
| 2 | Authorized shares doubled | 200,000,000 → 400,000,000. Explicit capacity for another ~205M shares without a further vote. |
| 3 | MASH reads out in 2029 | PERFORMA Phase 3 initiated August 2026, 52-week data 2029. A three-year dead zone on the lead indication. |
| 4 | $519M does not fund two Phase 3 programmes | Q2 opex was $26.2M, but PERFORMA is at start-up cost. At full global enrolment, plus an AUD Phase 3, R&D plausibly reaches $40–60M per quarter. Realistically ~3 years of funding against a 2029 readout — they will need to partner or raise again before the data. |
| 5 | Accumulated deficit $694.9M, zero product revenue ever | Revenue in the last four fiscal years: $41K, $20K, $426K, −$68K. Effectively nil. |
| 6 | The most crowded field in pharma | GLP-1 is dominated by Lilly and Novo with a dozen fast followers. See Knowledge/Themes/glp1-obesity-pharma — the largest therapeutic category in pharma history and simultaneously the clearest case of a huge field with losing economics for subscale entrants. |
| 7 | The AUD trial is small and short | RECLAIM randomized ~100 patients over 24 weeks. Addiction endpoints carry high placebo response; a 100-patient, 24-week result is a real signal but a thin base for a Phase 3 commitment. |
| 8 | Warrant overhang beyond the share count | The April 2026 offering included pre-funded warrants and common stock warrants (two tranches). Fully diluted exceeds the 194.5M reported. |
| 9 | Short interest 27% of float | ~23% of shares outstanding (float 164.39M of 194.52M). |
| 10 | Sell-side is the most stale of the three | Mean target $17.22 against $2.94 — a 5.9x gap. |
| 11 | Interest income is 17% of opex | $4.5M per quarter against $26.2M of spending. A rate-cutting cycle quietly worsens the burn without anything operational changing. |
| 12 | Insider ownership is ~0% | The CEO holds 62,500 shares — about $184K — after buying. The buying is genuine (§6) but the absolute alignment is small. |
| 13 | Headquarters relocation | Moving to Morristown, New Jersey in 2026. Cash out the door for a company with no revenue. |
| 14 | EPS "improvement" is a dilution artifact | Net loss per share went $(0.27) → $(0.12) YoY while the absolute net loss rose from $22.1M to $22.8M. The ratio improved only because the share count grew 128%. Per Knowledge/Playbook/pitfall-growth-ratio-against-collapsing-base, read the absolute number. |
Golden flags
| # | Flag | Detail |
|---|---|---|
| 1 | Six verified open-market insider purchases, zero sales | Every one confirmed transaction code P on EDGAR. See §6. The strongest insider configuration of the three names. |
| 2 | The CEO bought again AFTER the data | Durso purchased 15,000 shares at $2.95 on 2026-08-13, two weeks after the positive AUD readout and with the stock near its 52-week low. |
| 3 | $519M liquidity, no near-term financing gun | Roughly 4–6 years at the current run rate. Total liabilities are only $53.0M. |
| 4 | Trades at 1.21x book, and book is almost all securities | Stockholders' equity $474.2M against a $571.7M market cap. |
| 5 | Two FDA designations | Breakthrough Therapy in MASH (on 24-week IMPACT Phase 2b data) and Fast Track in AUD. |
| 6 | RECLAIM hit the primary and registrational secondaries | Statistically significant reduction in heavy drinking days, plus 2-level WHO risk-drinking reduction and zero heavy drinking days — both recognized by FDA as registrational endpoints. The Phase 3 endpoint path is therefore already defined. |
| 7 | AUD is genuinely uncrowded | Everyone else points this mechanism at obesity and MASH. Roughly 29M US adults have alcohol use disorder and under 10% receive any pharmacotherapy. Differentiation from the GLP-1 scrum is real. |
| 8 | A third shot: ALD | RESTORE Phase 2 fully enrolled, protocol amended to a Week 48 primary on liver stiffness, topline 2H 2027 — a genuine mid-term catalyst inside the MASH dead zone. |
| 9 | Institutional ownership 78% |
3. Fundamentals
Income statement
| Line ($M) | Q2 2026 | Q2 2025 | 1H 2026 | 1H 2025 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | 0.005 | — | 0.010 | 0.041 |
| R&D | 18.66 | 17.24 | 34.85 | 33.06 | 66.43 |
| G&A | 7.57 | 5.69 | 15.63 | 11.68 | 28.06 |
| Total opex | 26.23 | 22.93 | 50.47 | 44.75 | 94.49 |
| Interest income | 4.53 | 1.13 | 7.43 | 2.68 | — |
| Interest expense | (1.10) | (0.26) | (2.17) | (0.27) | (1.64) |
| Net loss | (22.83) | (22.15) | (45.39) | (41.72) | (88.09) |
| EPS | (0.12) | (0.27) | (0.29) | (0.53) | (1.00) |
| Weighted avg shares | 185.4M | 81.5M | 155.1M | 78.5M | 88.1M |
Of Q2 R&D, $11.6M was direct pemvidutide development — the rest is infrastructure. The increase over Q2 2025 is PERFORMA start-up plus the ongoing ALD trial, partly offset by IMPACT completing.
Balance sheet (2026-06-30)
| Item | Value |
|---|---|
| Cash, equivalents and restricted | $63.05M |
| Short-term investments | $263.27M |
| Long-term investments | $192.25M |
| Total liquidity | $518.57M |
| Total assets | $527.21M |
| Total current liabilities | $12.50M |
| Term loan, noncurrent | $34.74M |
| Total liabilities | $53.00M |
| Stockholders' equity | $474.21M |
| Accumulated deficit | $694.87M |
| Shares outstanding | 194,474,154 (400M authorized) |
How the dilution happened
| Period | Event | Shares | Net proceeds |
|---|---|---|---|
| Q1 2026 | Registered direct offering | 12,397,920 | $51.06M |
| Q1 2026 | ATM | 2,021,169 | $8.74M |
| Q1 2026 | Pre-funded warrant exercises | 4,647,534 | $19.28M |
| Q2 2026 | Public offering (April) | 64,250,000 | $180.76M |
| Q2 2026 | Pre-funded warrants in same offering | — | $30.30M |
| 1H26 total financing inflow | $289.54M |
The April offering was $225.0M gross, oversubscribed. This is the single most important fact about the balance sheet and the single most important red flag simultaneously: they raised at $3.00-ish into strength before the AUD data, which was well-timed corporate finance and severe dilution at the same time.
Survival metrics
| Metric | Value |
|---|---|
| Net liquidity | $483.9M |
| Current burn rate | ~$75M/yr (net loss less non-cash, plus interest income offset) |
| Runway at current burn | ~6 years |
| Runway at realistic Phase 3 burn ($150–200M/yr) | ~2.5–3 years |
| Debt | $34.7M term loan |
| Going-concern language | None — 10-Q states 12+ months (standard ASC 205-40 phrasing) |
| Dilution, last 6 months | +75.4% |
This is the crux. ALT does not have a survival problem, it has a time problem. The distinction matters: most failures in this cohort come from running out of money before the catalyst. ALT will not. It may instead arrive at 2029 having diluted twice more.
4. Moat & market
No moat today. A possible one forming in AUD.
Pemvidutide is a 1:1 balanced glucagon/GLP-1 dual agonist. In MASH and obesity, there is no defensible position — this is the single most contested mechanism in pharmaceutical history, and ALT is competing against Lilly and Novo with a fraction of their capital. Breakthrough Therapy Designation is meaningful but it is a regulatory courtesy, not a competitive barrier. A 2029 readout in a field moving this fast is a serious strategic liability on its own.
The AUD position is different, and it is the actual thesis. Roughly 29 million US adults have alcohol use disorder; fewer than 10% receive any pharmacotherapy, and the approved options (naltrexone, acamprosate, disulfiram) are old, modestly effective and rarely prescribed. Nobody large is pointing a GLP-1/glucagon agonist at addiction as a lead indication. First mover with Fast Track and FDA-recognized registrational endpoints in an indication with essentially no modern competition is a genuine moat-in-the-making.
Adversarial stress-test — "a well-funded rival decides to enter." This is where the case weakens badly. Lilly and Novo both have GLP-1 assets already approved and already generating data on alcohol consumption as a secondary observation. If AUD becomes a commercially attractive indication, either of them can run a Phase 3 in it with a marketed drug and vastly better economics, and neither needs to buy ALT to do it. This is precisely the framework's warning about "a small team inside a larger company" — except here the larger companies already have the molecule, the manufacturing and the salesforce.
ALT's defence is being first with a purpose-built trial and a differentiated mechanism (the glucagon component drives liver-specific effects that pure GLP-1s do not). Whether that is sufficient is the open question, and it is a five-year question, not a five-month one.
Evergreen: no. A clinical-stage asset in a contested mechanism.
5. Valuation
| Model | Applicability | Result |
|---|---|---|
| Graham IV | N/A — no earnings | — |
| DDM / DYT | N/A — no dividend | — |
| P/B | Meaningful here — book is ~90% liquid securities | 1.21x |
| Net liquidity per share | Primary | $2.49 |
| Implied EV | Primary | ~$88M |
Scenario frame:
| Scenario | Assumption | Value/share |
|---|---|---|
| AUD Phase 3 abandoned / partner never comes | Burn to 2029 on MASH alone, dilute twice | $1.50 – $2.20 |
| Status quo — funded, no new information | Trades near liquidity value less burn | $2.40 – $3.00 |
| AUD Phase 3 initiated with a partner | Partner funds development, validates mechanism | $5.00 – $7.00 |
| AUD Phase 3 succeeds (2029+) | First-in-class in a 29M-patient indication | $12 – $20+ |
| MASH Phase 3 succeeds (2029) | Small share of a huge but crowded market | $8 – $15 |
Fair value range: $2.50 – $6.00 on a 2–3 year view, with the wide right tail excluded because it is too far out to discount responsibly.
At $2.94 the stock trades at roughly net liquidity plus a nominal option premium. The market is assigning the pipeline almost nothing. That is either an enormous mispricing or a correct assessment that $519M gets consumed by 2029 with two more raises along the way.
Trim discipline: this resolves on clinical and partnership outcomes, not on a multiple. A valuation-multiple trim is the wrong instrument for a pre-revenue asset.
6. Sentiment & Intelligence
Insider buying — verified, repeated, and the strongest signal in this entire review.
Every purchase below carries transaction code P (open-market purchase), confirmed by pulling Form 4s directly from EDGAR rather than trusting the vendor summary:
| Date | Insider | Role | Shares | Price | Code |
|---|---|---|---|---|---|
| 2026-08-13 | Jerome B. Durso | President & CEO | 15,000 | $2.95 | P ✓ verified |
| 2026-04-06 | John M. Gill | Director | 9,200 | $3.4076 | P ✓ verified |
| 2026-04-01 | Gregory L. Weaver | CFO | 10,000 | $3.15 | P |
| 2026-04-01 | Jerome B. Durso | CEO | 15,000 | $3.14 | P |
| 2026-03-06 | Gregory L. Weaver | CFO | 5,000 | $3.54 | P |
| 2026-03-06 | Jerome B. Durso | CEO | 20,000 | $3.54 | P |
Six purchases, three individuals, four separate dates, zero sales. The CEO bought three separate times, most recently two weeks after the positive AUD readout, at a price near the 52-week low. Separately-dated stock awards (2026-07-31 at $2.41, 2026-01-30 at $5.60) are correctly labelled as grants and excluded.
Per Knowledge/Playbook/pitfall-yahoo-insider-purchases-counts-rsu-grants, the test for genuine
buying is cash paid at or near the prevailing market price, verified in the Form 4 rows. These
clear it unambiguously. Contrast with CMPX, where the equivalent claim collapsed on inspection,
and with SPRY, where nobody bought at all.
The honest qualifier: the CEO holds only 62,500 shares in total (~$184K). This is a directional signal from people with information, not founder-scale alignment.
Management communication. The Q2 release is straightforward and does not overreach — it reports the AUD primary endpoint as met, states the FDA-recognized status of the secondaries factually, and gives a 2029 date for MASH without dressing it up. Notably, they did not announce an AUD Phase 3; they said they would request an End-of-Phase 2 meeting. That is appropriate caution, and it is also a tell that the funding for an AUD Phase 3 is not yet settled.
Why the stock is near lows after positive data — the question the analysis has to answer. The most likely explanation is not that the data was bad. It is that the market read the April raise plus the 2029 MASH timeline plus the absence of a Phase 3 commitment in AUD as: good result, no near-term path to monetize it, and more dilution coming. That reading is defensible. It is also exactly the condition under which insiders buying is worth paying attention to.
Ratings. Attitude: measured, non-promotional. Health: strongest of the three. Trajectory: scientifically advancing, commercially distant. Investor attitude: 27% of float short, 78% institutional, sell-side stale by 5.9x. Financial pressure: low near-term, high on a 3-year view.
7. Catalysts
| Catalyst | Date | Likelihood | Impact | Direction |
|---|---|---|---|---|
| AUD End-of-Phase 2 FDA meeting outcome | Late 2026 / early 2027 | High | High | Both |
| Partnership on pemvidutide (AUD or MASH) | Any time | Medium | Very high | Up |
| AUD Phase 3 initiation and funding plan | 2027 | Medium-high | High | Both |
| European regulatory engagement on AUD | 2026–2027 | Medium | Medium | Up |
| RESTORE ALD Phase 2 topline | 2H 2027 | High | High | Both |
| Further equity raise | 2027–2028 | High | Medium | Down |
| PERFORMA MASH 52-week data | 2029 | High | Very high | Both |
The partnership is the catalyst that matters most. ALT cannot fund two Phase 3 programmes to completion alone. A partner would simultaneously solve the funding problem, validate the mechanism, and remove the dilution overhang — which is why it would re-rate the stock far more than the data already has. Its absence so far, after Breakthrough Therapy Designation and a positive AUD readout, is itself a data point worth watching.
8. Verdict
WATCH. Conviction 6.0 — the highest of the three. Risk rating: ASYMMETRIC-BET. Red flags 14, golden flags 9.
Bull case. You are paying roughly 45 cents a share above net liquidity for a Phase 3-stage franchise with Breakthrough Therapy Designation in MASH, Fast Track in AUD, a positive Phase 2 with registrational endpoints already met, and a third readout coming in 2027. The company has $519M and no meaningful debt, so unlike almost everything else in this cohort it cannot be forced into a financing at a distressed price. The CEO, CFO and a director have bought in the open market six times with zero sales, including two weeks ago after the data. AUD is a large, genuinely neglected indication where ALT is first with a purpose-built trial. If a partner appears, this re-rates hard before any Phase 3 result exists.
Bear case. The share count rose 75% in six months and the authorization was doubled to 400 million, which tells you what management expects to do next. The lead indication does not read out until 2029 in the most competitive mechanism in pharma, against two companies with vastly more capital and marketed products. $519M does not fund two Phase 3 programmes to completion — at a realistic $150–200M annual burn it is closer to three years than six, so more dilution is close to certain before any of this resolves. The AUD result rests on 100 patients over 24 weeks. And if AUD proves commercially attractive, Lilly or Novo can enter with an approved drug and never need to acquire ALT. A cheap enterprise value on an asset that takes three more years and two more raises to test is not the same thing as a cheap stock.
Weighing it. Under analysis_notes.md §5, for a pre-revenue clinical name, Sentiment and Moat
outweigh static valuation — and here Sentiment (verified insider buying) and Fundamentals
(unassailable near-term balance sheet) both point the same way, while Moat points the other. The
tension is real and it is a time tension, not a survival tension. That is the better of the
two problems to have, and it is what separates ALT from the rest of the names screened.
Position sizing
A portfolio-specific passage was removed from the public build.
Even so: lottery ticket, sized as one. At most 0.5–1.0% of portfolio value, entered with the expectation of total loss in the bad branch. Belongs in Speculative & Micro, never in Evergreen or Income.
Recommended action: WATCH at conviction 6.0, entry zone $2.60–3.10. Of the three names reviewed this is the one where a small starter position is most defensible today — the balance sheet removes the near-term ruin risk, the insider buying is verified rather than assumed, and the implied $88M enterprise value is genuinely anomalous. But there is no urgency: the MASH dead zone runs to 2029 and the next real catalyst (the End-of-Phase 2 meeting outcome) has no fixed date. Nothing is lost by waiting for either that outcome or a partnership announcement.
Sources
- Altimmune 10-Q for the quarter ended 2026-06-30, filed 2026-08-12 (SEC EDGAR, CIK 0001326190) — balance sheet including $192.2M long-term investments, opex detail, equity rollforward, share authorization increase
- Q2 2026 results and business update (8-K Ex-99.1, 2026-08-12) — $519M liquidity, PERFORMA initiation with 2029 readout, RECLAIM results, Fast Track, RESTORE enrolment and 2H 2027 topline, $225.0M April offering
- Form 4 filed 2026-08-13, accession 0001698665-26-000007 (Durso) — code P, 15,000 @ $2.95
- Form 4 filed 2026-04-06, accession 0001409939-26-000002 (Gill) — code P, 9,200 @ $3.4076
- RECLAIM Phase 2 topline
Knowledge/Themes/glp1-obesity-pharma— field-level context on GLP-1 competitive economicspython .mcp/fin.py ALT --holdersretrieved 2026-08-20